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Abstract 
Background: The control of malaria in pregnancy in much of Asia relies on screening asymptomatic women for 
malaria infection, followed by passive case detection and prevention with insecticide-treated nets. In 2012, Indonesia 
introduced screening for malaria by microscopy or rapid diagnostic tests (RDTs) at pregnant women’s first antenatal 
care (ANC) visit to detect and treat malaria infections regardless of the presence of symptoms. Acceptability among 
health providers and pregnant women of the current ‘single screen and treat’ (SSTp) strategy compared to two alter-
native strategies that were intermittent preventive treatment (IPTp) and intermittent screening and treatment (ISTp) 
was assessed in the context of a clinical trial in two malaria endemic provinces of Eastern Indonesia.
Methods: Qualitative data were collected through in-depth interviews with 121 health providers working in provi-
sion of antenatal care, heads of health facilities and District Health Office staff. Trial staff were also interviewed. Focus 
group discussions were conducted with 16 groups of pregnant women (N = 106) to discuss their experiences of each 
intervention in the trial.
Results: Health providers and pregnant women were receptive to screening for malaria at every ANC visit due to the 
increased opportunity to detect and treat asymptomatic infections. A primary concern for providers was the accu-
racy and availability of RDTs used for screening in the SSTp and ISTp arms, which they considered less accurate than 
microscopy. Providers had reservations about giving anti-malarials presumptively as IPTp, due to concerns of causing 
potential harm to mother and baby and as a possible driver of drug resistance. Pregnant women were accepting of 
all three interventions. Women in the IPTp arm were happy to take anti-malarials presumptively to protect themselves 
and their babies against malaria.
Conclusions: The findings indicate that, within a trial context, malaria screening of pregnant women at every ANC 
visit ISTp was an acceptable strategy among both health providers and pregnant women owing to an existing culture 
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Background
Malaria in pregnancy has adverse consequences for both 
mother and baby. In Indonesia, 6.4 million pregnancies 
are exposed to malaria annually [1]. Malaria transmis-
sion varies from low to moderate with Plasmodium fal-
ciparum and Plasmodium vivax as the dominant species. 
Malaria infection in pregnancy in areas of low or unstable 
transmission, where women have little acquired immu-
nity, is more likely to result in symptomatic malaria, 
severe disease and death of the mother or baby than in 
areas of moderate-to-high transmission. Both P. falcipa-
rum and P. vivax infections in pregnancy are associated 
with severe maternal anaemia, fetal loss and a reduction 
in mean birth weight or low birth weight babies [2, 3]. 
In Papua, asymptomatic and submicroscopic infections 
constitute two-thirds of detectable parasitaemia and are 
associated with a high risk of anaemia [4].
The control of malaria in pregnancy in most parts 
of Asia relies on screening asymptomatic women for 
malaria infection followed by passive case detection 
(PCD) and management of symptomatic malaria, and 
prevention with long-lasting insecticide-treated nets 
(LLINs) [5, 6]. Indonesia was the first country in Asia to 
introduce, in 2012, malaria screening as part of antena-
tal care (ANC) and to adopt dihydroartemisinin-pipe-
raquine (DP) as first-line treatment for malaria in the 
second and third trimesters of pregnancy. The screening 
strategy consists of screening all pregnant women at the 
first ANC visit with either microscopy or rapid diagnos-
tic tests (RDT), and treatment of test-positive cases with 
the nationally recommended anti-malarial (DP in 2nd or 
3rd trimester and quinine in 1st trimester), henceforth 
referred to as ‘single screening and treatment (SSTp)’ [7]. 
However, a limitation of SSTp is the lack of prevention of 
re-infections later in pregnancy or missing asymptomatic 
cases in late pregnancy.
Weekly screening for malaria by microscopy and treat-
ment of test positive women with effective anti-malarials 
substantially reduced maternal mortality from P. falcipa-
rum malaria in refugee camps on the Thai-Myanmar bor-
der [8], however such intensive screening programmes 
are unlikely to be feasible in routine health system set-
tings. Recent trials in sub-Saharan Africa [9–12] found 
intermittent screening and treatment in pregnancy (ISTp) 
with RDTs at every scheduled ANC visit (average of 3–6 
visits) and treatment of positive cases with artemisinin-
based combination therapy (ACT) was acceptable and 
potentially feasible [13–16]. However, recent results from 
the clinical trials indicate that, with the current genera-
tion of malaria RDTs, ISTp was not a suitable alternative 
strategy to intermittent preventive treatment with sulf-
adoxine–pyrimethamine (IPTp-SP), even in areas with 
high prevalence of SP resistance in East and Southern 
Africa [12].
A cluster-randomized controlled trial was undertaken 
between May 2013 and November 2016 to compare the 
efficacy of IPTp or ISTp with DP versus the current policy 
of SSTp with DP in the 2nd and 3rd trimester in prevent-
ing the adverse outcomes of malaria in pregnancy in an 
area of relatively low P. falciparum and P. vivax transmis-
sion in eastern Indonesia. The objective of this study was 
to assess the acceptability and perceptions of health pro-
viders and pregnant women towards ISTp and IPTp com-
pared to SSTp in the context of the clinical trial. Should 
the efficacy trial indicate that a shift to either ISTp or 
IPTp is superior to the current strategy of SSTp in pre-
venting the adverse outcomes of malaria in pregnancy, 
then understanding the acceptability among pregnant 
women and health providers of the different strategies 
will help inform programme implementation and the 
communication strategy needed to promote effective 
delivery by providers and facilitate uptake by pregnant 
women.
Methods
A qualitative study was conducted in two rural districts 
in Eastern Indonesia, in South West Sumba District and 
in Timika sub-district of Mimika District, the same study 
sites where the main trial was conducted. In depth inter-
views (IDIs) with health providers in South West Sumba 
were conducted between May and July 2015 and in Mim-
ika between February and April 2016. Focus group dis-
cussions (FGDs) with women at both sites took place in 
December 2016.
Study sites
Mimika District lies in the south of Papua Province, East-
ern Indonesia, covering 19,952 square kilometres consist-
ing of highlands and lowlands. It has a rapidly growing 
population of an estimated 182,000 (2010 census) Papuan 
of screening and treatment. The adoption of IPTp however would require a considerable shift in health provider 
attitudes and a clear communication strategy. By contrast, pregnant women welcomed the opportunity to prevent 
malaria infections during pregnancy.
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and non-Papuan Indonesians, with the main occupa-
tions in commerce, business, and retail. The prevalence 
of parasitaemia among pregnant women at delivery is 
16.8% (58% P. falciparum infections, 34% P. vivax, and 
8% mixed infections), with 35% of these infections being 
associated with fever [3].
South West Sumba District is situated in a low vol-
canic island (Sumba) occupying 1445 sq km in East Nusa 
Tenggara Province. It has a population of 283,818 (2010 
census) of mainly native Sumbanese Indonesians and 
the main occupation is subsistence farming. Malaria on 
the island is seasonal, with a dry season from May to 
November and a wet season from December to April. In 
2012, the antenatal prevalence of infection in pregnancy 
was 3–5% by RDT or microscopy and 7% by Polymerase 
chain reaction (PCR) [17].
The main health facilities which deliver ANC services 
to pregnant women are hospitals, community health 
centres (known in Indonesian as puskesmas) covering 
about 30,000 people, sub health centres (pustu) which 
serve about 2–3 villages and 2000–3000 population, and 
health posts (posyandus) or community integrated ser-
vices including antenatal care, which are held monthly 
or bi-monthly in villages. The trial selected ANC facili-
ties which had more than 10 new pregnancies per year 
and were located within 1.5 h drive from the study offices 
in each site [Ahmed, personal communication]. ANC 
attendance in Mimika and South West Sumba districts is 
similar, with 84% and 87% of pregnant women making at 
least one ANC visit, respectively [18, 19]. Only a third of 
women (32%) make at least 4 ANC visits in Mimika; data 
for West Sumba was not available. The key indicators for 
ANC utilization captured in the ANC registers are: ‘K1 
pure’ which measures 1st ANC visit in the first trimester, 
and ‘K1 contact’ which measures first ANC visit in 2nd or 
3rd trimester.
Trial context
The main trial was an open-label three-arm parallel-
group matched cluster-randomized controlled superi-
ority trial in two sites (Mimika District and South West 
Sumba) comparing the efficacy, safety and cost-effec-
tiveness of IPTp and ISTp vs the current SSTp strat-
egy. DP was used in all 3 arms (Trial registration no. 
ISRCTN34010937). The study selected health centres 
(puskesmas) and their related health posts (pustu or 
posyandu) in each trial site to enroll pregnant women. 
Recruitment began in May 2013 and the last case follow-
up of infants was completed in November 2016. Par-
ticipants received one of the three interventions at each 
scheduled ANC visit during the 2nd and 3rd trimesters 
of pregnancy according to the randomly allocated cluster. 
Visits were scheduled every 4 weeks (± 3 days) with the 
total number of ANC visits ranging from 3 to 6 (median 
3). The trial used First Response Malaria Ag pLDH/HRP2 
Combo RDTs (Premier Medical Corporation Pvt Ltd, 
India) as the point of care test for malaria screening.
In‑depth interviews with health providers
All health facilities involved in the clinical trial were 
included in the study, comprising 10 health centres 
(puskemas) and their related health posts (posyandus) 
in South West Sumba and 7 health centres in Mimika 
plus staff from the District health Office (DHO) and staff 
involved in the clinical trial from each district.
IDIs were conducted with health providers who were 
purposively selected according to their role in the deliv-
ery of antenatal services, including midwives, doctors, 
laboratory staff, pharmacists, head of drug store, and the 
facility head. In Sumba, facility and drug store heads had 
no involvement with antenatal service delivery and were 
not selected. The consent of the head of the health facility 
was first sought and, subject to consent, staff selected for 
interview were then invited to give written consent to be 
interviewed at a convenient time.
Interviews were conducted using an interview guide 
to explore the following themes: (1) their acceptability of 
SSTp, ISTp and IPTp; (2) their perceptions of pregnant 
women’s acceptability of each trial arm; (3) their per-
ceptions of the feasibility of implementing each of the 
interventions at scale, and (4) their recommendations on 
factors to be considered to ensure effective implementa-
tion. Interviewers adopted an iterative process whereby 
any emergent themes raised by participants relevant to 
the objectives of the study were explored further and/or 
included in subsequent interviews. The interviews were 
conducted in Indonesian in both sites by trained staff, 
and digitally recorded.
Focus group discussions with pregnant women
FGDs were conducted with participants in both South 
West Sumba and Mimika districts in December 2016, 
after follow up of trial participants was completed so 
that experiences from a full pregnancy history could 
be obtained for each woman. Women were purposively 
selected using the study database to represent views 
and experiences from each of the three trial arms and to 
ensure a mix of women in the two screening arms who 
tested positive and negative to malaria during the trial. 
A total of 16 FGDs were carried out, 7 in South West 
Sumba and 9 in Mimika comprised of women from 6 
different groups: (1) ISTp arm, RDT negative, (2) ISTp 
arm, RDT positive, (3) SSTp arm, RDT negative, (4) SSTp 
arm, RDT positive, (5) IPTp arm, and (6) a heterogenous 
group with women from all three interventions groups. 
Due to low malaria incidence in both sites, FGDs with 
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RDT positive women were not conducted in Sumba, and 
only one FGD with RDT positive women for both ISTp 
and SSTp arms was conducted in Mimika.
Data management and analysis
In-depth interviews and FGDs were transcribed and 
translated into English by external translators and 
checked by the trial Research Assistant for any diver-
sion in meanings of the content. The  transcripts were 
then entered into NVivo Version 11.2 for data manage-
ment and analysis. The data were coded by J Hoyt and 
analysed by J. Hoyt, J. Hill and J. Webster; any conflicting 
views were discussed among the team until a consensus 
was reached. A similar framework to that used in a previ-
ous study [14] was used to structure the interview theme 
guide was also used for coding and initial analysis of the 
IDIs. Each of the intervention arms were further coded 
according to the WHO health systems building blocks 
[20]: financing, governance, health information, human 
resources, products and technology, and service delivery. 
The framework used to analyse the FGDs comprised of: 
experiences and acceptability of the interventions as a 
whole and their individual components (i.e. malaria test-
ing and anti-malarials); and adherence to anti-malarials 
for treatment (SSTp and ISTp) and prevention (IPTp). 
A content analysis approach was used to derive emer-
gent themes and sub-themes considered important to 
the acceptability of the trial interventions, and relevant 
quotes used to enrich and support the findings.
Results
Interviews were conducted with 121 health providers; 
50 health providers from 10 health centres, four DHO 
staff and two trial staff in South West Sumba (n = 56), 
and 56 health providers from 7 health centres, five DHO 
staff and four trial staff in Mimika (n = 65). A list of cad-
res interviewed can be found in Table  1. A total of 106 
women participated in 16 FGDs in the two sites. Sum-
mary characteristics of the women can be found in 
Table 2. The women were aged between 16 and 44 years 
and most were married (88%) and had reported between 
1 and 8 pregnancies. Key themes emerging from the anal-
ysis of data from health providers and pregnant women 
are presented here together with illustrative quotes, and 
a summary of themes from both groups of participants is 
presented in Table 3. Quotes supporting the sub-themes 
are provided in Additional files 1 and 2.
Health providers
Acceptability of current policy—SSTp
Health providers in South West Sumba and Mimika were 
supportive of the current policy of SSTp. Many cited the 
importance of early detection and treatment of malaria 
in pregnancy as a key benefit of the strategy. There was 
acknowledgment that women are often asymptomatic 
during pregnancy thus screening at the first ANC visit 
regardless of symptoms was important to protect both 
mother and baby.
Health providers in Sumba discussed the challenges 
posed by the lack of resources needed to carry out the 
SSTp strategy in the national programme and reported 
that, without reliable supplies, they were unable to imple-
ment the policy consistently. Frequent reports of RDT 
stock-outs meant SSTp was often not being implemented 
at the health posts, which have no access to microscopy. 
These reports of stock-outs refer to time periods outside 
the trial, since RDTs and DP were supplied to all partici-
pating facilities during the trial.
One village midwife from Mimika mentioned that 
screening once in pregnancy was not enough to offer full 
protection to mother and baby, while two participants felt 
that testing only symptomatic women would be sufficient.
Acceptability of trial interventions—ISTp
There was strong support for ISTp from the health pro-
viders across all sites. The main benefit reported was that 
screening at every ANC visit would provide women with 
more complete protection as they could contract malaria 
at any time during their pregnancy.
“R: As I know, sometimes the pregnant woman who 
had malaria screening and treatment at K1 [1st 
ANC visit] believed that she had no malaria any-
more. However, we were not sure whether she got 
malaria infection when she went home [after she was 
identified negative during the first visit at clinic]. 
That’s why it will be better if the pregnant woman is 
screened at every antenatal care visit every month 
so we can make sure that the pregnant woman is 
Table 1 Health provider cadres interviewed at  Sumba 
and Mimika sites
a Puskesmas—health centres
Sumba Mimika Total
Head of  puskesmasa 0 7 7
Doctor 10 7 17
Lab technician 10 7 17
Malaria coordinator 11 8 19
Midwife coordinator 11 8 19
Village midwife 10 7 17
Pharmacist 1 8 9
Head of drug store 0 8 8
Head of DHO 1 1 2
Trial staff 2 4 6
Total 56 65 121
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free from malaria until the day of delivery.” Malaria 
coordinator, SUMBA
For some, ISTp was the best option among the three 
interventions for reasons including a preference for test-
ing before giving anti-malarials, and continuous testing 
throughout pregnancy provided more comprehensive 
coverage.
However, not all participants felt that testing at every 
visit was the best option. Some providers worried about a 
reliance on RDTs, which were often not available through 
the national programme, and about insufficient resources 
generally, including reagents for microscopy. Other pro-
viders felt that women might complain about being 
tested at every visit and one midwife commented that 
they might be too busy to screen women at every visit. 
Several providers said the current strategy of screening 
at the first ANC visit and subsequently if symptomatic 
(SSTp) was sufficient.
“I: Is there any problem so far in screening test using 
RDT method? R: The unavailability of RDT kit itself 
is a problem. I didn’t know what causes it.” Village 
midwife, SUMBA
Acceptability of trial interventions—IPTp
Health providers at both sites expressed concern with 
regards to the IPTp strategy. Most frequently reported 
across all cadres was the assertion that women should 
be tested for malaria before being given anti-malarials 
and, closely related, that taking medication in pregnancy, 
particularly if there was no disease present, could cause 
harm to mother and/or baby. Malaria coordinators, doc-
tors and one head of facility worried that the provision 
of preventive anti-malarials could accelerate resistance to 
key drugs.
“I: What do you think about giving anti-malarial 
drugs without screening? R: It is not allowed. The 
diagnosis of malaria has to be confirmed first before 
we give the drug. We can’t make diagnosis of malaria 
by bare eyes. We cannot determine malaria cases by 
looking at their symptoms because the symptoms 
may be due to another disease.” Malaria coordina-
tor, MIMIKA
Several midwives, a doctor and one facility head were 
open to the idea of giving preventive doses of anti-malar-
ials to women under the belief that prevention was a 
good idea. Furthermore, providers who were asked spe-
cifically about giving drugs without screening as “preven-
tive” within the context of a clinical trial were more likely 
to show acceptance towards IPTp than those who were 
asked the question out of context.
“I: Relating to the IPTp method that we should give 
anti-malarial drug without screening, what do you 
think about that? R: I am not sure whether it is safe 
or not if we [just] administer [malaria] drug with-
out assessing whether they have malaria symptoms 
I: So, do you disagree with that method? R: However, 
as long as there is a guideline for this method, I have 
no problem to implement [IPTp]” Village midwife, 
SUMBA
Among providers who did not disagree with IPTp many 
were still hesitant about the strategy with concerns about 
women not wanting to take medication if they don’t feel 
ill, safety of the drugs, additional communication with 
Table 2 Summary characteristics of pregnant women participating in the focus group discussions
a Due to low malaria incidence FGDs with IST or SST positive women did not take place in Sumba
b 12 out of the 16 women reported their age
c 15 out of the 16 women reported their age
Site Trial  arma Number of focus 
group discussions 
(FGDs)
Number 
of participants 
(n)
Average age (range) Marital status (n) Average number 
of pregnancies 
(range)
Sumba IST negative 2 16 30 (24–42)b Married (10), single (6) 3 (1–8)
Mimika IST negative 2 16 29 (20–40)c Married (14), single (2) 3 (1–5)
Sumba SST negative 2 11 34 (24–42) Married (8), single (3) 4 (1–6)
Mimika SST negative 2 12 27 (18–39) Married (12), single (0) 2 (1–8)
Mimika IST positive 1 7 25 (16–32) Married (7), single (0) 2 (1–5)
Mimika SST positive 1 6 33 (25–42) Married (6), single (0) 4 (2–6)
Sumba IPTp 2 10 27 (20–32) Married (9), single (1) 2 (1–4)
Mimika IPTp 2 16 26 (16–40) Married (15), single (1) 2 (1–6)
Sumba Heterogenous 1 6 33 (25–44) Married (6), single (0) 3 (2–4)
Mimika Heterogenous 1 6 24 (19–37) Married (6), single (0) 2 (1–4)
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women and increased workload to follow-up adherence 
to drugs. A few midwives recalled the earlier practice 
of chloroquine prophylaxis during pregnancy and their 
responses were mixed as to whether they felt it was a 
good programme or not.
Perceptions of pregnant women’s attitudes towards trial 
interventions
Although providers were not directly asked about preg-
nant women’s acceptability towards elements of the 
trial interventions, some participants volunteered their 
perceptions on how women felt about malaria screen-
ing and the three trial arms. In general, they felt women 
were happy to be screened for malaria, despite a few 
women who were concerned with the amount of blood 
being taken (referring to the venous blood taken at the 
first ANC visit). One trial staff was asked if they would 
be charged for the test and one midwife reported hear-
ing that some women in the ISTp arm complained about 
being tested every visit.
Trial staff involved in the IPTp arm reported that some 
women experienced side effects after taking DP including 
Table 3 Themes on the acceptability of ISTp and IPTp among pregnant women and health providers
DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment, ISTp intermittent screening and treatment, MiP malaria in pregnancy, RDTs rapid 
diagnostic tests, SSTp single screening and treatment
a Indicates when it is a health provider perception of how pregnant women feel
Theme Pregnant women Health provider
SSTp
 Major themes Happy to be screened for malaria Early detection and treatment is very important
Stocks of RDTs were not stable
Malaria in pregnancy can be asymptomatic
 Minor themes Would prefer ISTp over SSTp Screening once is not enough
Testing when symptomatic is sufficient
ISTp
 Major themes Happy to be tested & know malaria status
Happy to be tested monthly
Happy to be tested even when asymptomatic
Screening at every visit is a good strategy
Women can contract malaria at any time in the pregnancy
Women are happy to be screened for  malariaa
 Minor themes Prefer testing only when symptomatic Some women may not like monthly  testinga
Asymptomatic screening at first visit is sufficient
RDTs
 Major themes Happy to receive results right away
Don’t mind the finger prick
Results are not always accurate
RDTs don’t detect all malaria species
Supply is not stable, frequent stock-outs
Fast and easy to use
Good for use at village posts, where lab services/electricity not available
 Minor themes Afraid of needle/blood loss Prefer RDT over microscope
IPTp
 Major themes Happy to take drugs to prevent malaria and be healthy 
(even with side effects)
Will take the drugs when reassured there is no harm to 
baby, given by trusted provider
Women should be tested before they are given anti-malarials
Taking medication during pregnancy when there is no disease could 
cause harm
Could increase drug resistance
 Minor themes Prefer testing before taking drugs
Hesitant at first to take drugs but did so for baby’s health
Prevention is a good idea, if the drug is safe
Some women may not want to take drugs if they are not  sicka
Some women in the IPTp arm refused 2nd dose of IPTp
DP anti-malarial
 Major themes Experienced side effects of nausea, dizziness, sleepiness
Completed my treatment/IPTp dose
Effective treatment for malaria
Well tolerated by women
Some reported side effects of nausea, vomiting, dizziness
 Minor themes Experienced vomiting
Did not complete my treatment/IPTp dose
Some refused to take subsequent IPTp doses
DP is hard and bitter
Service delivery
 Major themes Screening should be carried out at health posts, more accessible to women
Midwives should use RDTs at health posts to screen for MiP
Midwives should be able to give anti-malarials to women when necessary
 Minor themes Drugs should only be prescribed by doctors or nurses under supervision
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dizziness, nausea and vomiting. Staff said they had 
explained to women that the effects would not last long 
and highlighted the importance of protecting against 
malaria. Two trial staff at Mimika facilities reported that 
some women in some of the clinics refused to take subse-
quent doses of IPTp-DP when they returned to the ANC 
due to side effects.
Two midwives and one trial staff expressed concern 
that some women might not be willing to take medica-
tions if they were not ill. Other reactions by women 
in the IPTp-DP arm, as reported by health providers, 
included asking if DP was safe to take during pregnancy 
and comments that DP was hard and bitter. Two trial 
staff reported that informing women of the protective 
effects of IPTp-DP had motivated some women to take 
the drugs.
Acceptability of elements of trial interventions—RDTs 
and DP
At both Sumba and Mimika facilities and across health 
provider cadres, participants expressed serious doubts 
with regards to the accuracy of RDTs, with many report-
ing that they did not trust negative RDT results and 
would request a re-test using microscopy if women were 
symptomatic. Another limitation was that RDTs were 
perceived to only detect falciparum or mixed infections, 
leaving ovale or vivax infections undiagnosed. RDTs were 
considered useful as an alternative when microscopy was 
not available or during power outages. However, partici-
pants were quick to add that they preferred microscopes, 
as they were more accurate.
A smaller number of providers reported that RDTs 
worked well and many acknowledged that they were easy 
to use and provided faster results. Despite these benefits 
there were still concerns regarding accuracy. One doctor 
at a Sumba site stated a preference for RDTs saying that 
microscopy was subject to human error.
Availability of RDTs was a major issue for the current 
SSTp policy, with many participants of the FGDs and 
IDIs reporting frequent stock outs at their facility. These 
logistical issues were particularly pronounced at facili-
ties in Sumba, where supply issues in the national pro-
gramme negatively affected overall acceptability of RDTs 
as a screening tool and to ISTp as a potential alternative 
strategy.
Health providers reported that some women com-
plained about nausea, vomiting and dizziness after tak-
ing DP. Two midwives reported cases where a woman 
became “limp” after taking DP and there was one report 
of fatigue and headache. However, many providers said 
they received no reports of any negative side effects due 
to DP, and a few participants (mainly doctors and phar-
macists) said they preferred DP as it had fewer side 
effects and a shorter dosing schedule than quinine. One 
malaria coordinator and district level officer said that 
some midwives were nervous to give DP, fearing bad side 
effects.
“I: Any problem in DHP prescription? R: So far, 
there is none, and women often reported that they 
tolerated DHP and the experience of nausea was 
minimal. Patients feel comfortable to take DHP and 
recovered quickly after taking DHP.” Doctor, MIM-
IKA
Despite being first-line treatment for malaria in preg-
nancy and for non-pregnant patients, frequent stock outs 
of DP were widely reported by providers at all facilities 
in Sumba and at a few facilities in Mimika. The reason 
behind the stock outs was not well understood. Some 
facilities seemed to have a steady stock of DP, and a few 
participants reported that they had received DP either 
close to or past the expiry date.
Views on service delivery options of trial interventions
There was general approval among midwives for malaria 
in pregnancy screening to be carried out at rural health 
posts ‘pustu’ or ‘posyandu’, instead of at the health cen-
tres (puskesmas) as the health posts were more accessi-
ble to women, reducing transportation costs over long 
distances. There was strong acceptance among provid-
ers for midwives to screen pregnant women at the health 
posts with RDTs. However, microscopy was preferred for 
screening women at the health centres due to availability 
and accuracy. Midwives were generally more accepting 
of RDTs stating that the results were fast and the device 
easy to use.
Whilst it is not standard practice for midwives to give 
prescription drugs, there was cross-cadre acceptance 
for trained midwives to be allowed to give anti-malarials 
when necessary given the lack of pharmacists. A few pro-
viders in both sites felt drugs should only be prescribed 
by doctors, or nurses under supervision.
Pregnant women
Acceptability of screen and treat strategies (SSTp and ISTp)
Pregnant women were overwhelmingly positive about 
the benefits of being tested for malaria, knowing their 
status and receiving appropriate treatment. Further-
more, there was broad acceptance for regular testing 
despite being asymptomatic. Among women in the ISTp 
arm, most were happy to have regular blood tests and 
some women in the SSTp arms indicated a preference 
for monthly testing, even without symptoms, over SSTp. 
Encouragingly, several women said they would accept 
regular malaria tests in a future pregnancy, outside of a 
trial setting. A few women reported being initially afraid 
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about the blood test but understood its importance for 
their health and that of their baby. A few women in both 
Sumba and Mimika reported a preference for testing only 
when symptomatic.
“I: What did you feel when your blood was drawn? 
P8: I was shocked. I: Do you like blood drawing from 
your finger or not? P8: Yes, I do because then I could 
know whether I have malaria or not. Should we have 
malaria, then the drugs will be given. If malaria is 
not detected in our system then we are just happy 
because we check for it monthly.” ISTp negative, 
MIMIKA
Women from the RDT positive groups reported com-
pleting the treatment dose of DP except one woman who 
reported stopping after 1 day because she felt better and 
was afraid to keep taking the drugs.
Acceptability of anti‑malarials for prevention (IPTp)
The majority of women were happy to take preventa-
tive doses of DP as part of the IPTp strategy, despite 
experiencing side effects. A few women said they hesi-
tated because of fear of side effects but took them “for 
the health of the baby”. Commonly reported side effects 
after taking DP included nausea, dizziness and drowsi-
ness, with a few women saying they vomited shortly 
after taking the drug. Some women discussed a prefer-
ence for eating food before taking the dose at home as 
a way of preventing nausea. A few women reported a 
preference for testing before taking anti-malarials, even 
when described as “preventative”, and a small num-
ber of women said they felt confused about taking DP 
because they didn’t have malaria. However, the majority 
of women supported the preventative strategy if it was 
explained clearly, brought no harm to the baby and was 
administered by a trusted health provider. Most women 
reported completing the remaining two IPTp doses at 
home with no problems. A few women said they did not 
complete the dose due to size of DP, not having malaria 
or, in one case the woman’s husband used them to treat 
himself.
“I: So, you took the medicine that you knew was for 
malaria prevention? P2: Yes, because we knew it’s for 
malaria prevention, and more for our baby. Moreo-
ver, if my mum is also there, yes I had to take the 
drugs. I: So for the next pregnancy, will you take the 
drugs to for malaria prevention? All: Yes, I will. I: 
Why would you take the drug [malaria drug]? P5: 
Yeah, we want to take it, to keep our babies and 
ourselves healthy and free from malaria. I: What 
about if you still experience dizziness? P5: That’s 
alright. We need to ensure that mother and baby are 
healthy.” IPTp, MIMIKA
Discussion
This represents the first study evaluating provider and 
user acceptability of ISTp and IPTp with DP in the Asia 
region, and in a country where the current policy is SSTp. 
The qualitative data presented here demonstrates that 
among providers a shift from SSTp to ISTp would be a 
simpler conceptual step but that, with the proper com-
munication strategy, the IPTp strategy could be sup-
ported. Among pregnant women, both ISTp and IPTp 
were widely acceptable alternatives to SSTp. This study 
adds rich data on provider and user attitudes towards 
malaria in pregnancy control strategies and offers key 
insights for policy-makers regarding potential opportuni-
ties and challenges were Indonesia to shift from a screen 
and treat-focused policy to one that relies on presump-
tive use of anti-malarials.
Health providers were very receptive to ISTp as it pro-
vides more frequent opportunities to detect asympto-
matic infections over the course of pregnancy than SSTp. 
Many providers felt this was more comprehensive and 
better for mother and baby than the current SSTp policy. 
The primary concern with the ISTp strategy during the 
trial was the reliance on RDTs for screening. RDTs were 
considered less accurate than microscopy and their una-
vailability due to regular stock-outs in the national pro-
gramme was a limitation, particularly in Sumba. This 
concern is not unfounded as the current SSTp strategy 
relies on a stable supply of RDTs procured with external 
donor funding and is subject to fluctuations in funding 
levels. There is mounting evidence from studies else-
where that health providers regard RDTs as less accurate 
than microscopy but acknowledge their usefulness where 
resources are limited. Health providers in western Kenya 
described microscopy as the gold standard, while RDTs 
were considered useful in settings without laboratories 
or electricity but had limited sensitivity and specific-
ity [14]. Lack of trust in negative RDT results prompted 
some providers to advise re-checking RDT results using 
microscopy, as found in an evaluation of the SSTp strat-
egy in West Sumba and Mimika [21]. Provider mistrust 
was also reported in Uganda, where only 49% of health 
workers believed a negative result to be true [22]. Con-
cerns regarding RDT accuracy may be warranted as the 
results from the clinical trial indicate that, at current lev-
els of RDT sensitivity, subpatent cases were missed when 
RDTs were compared with more sensitive molecular test-
ing (Loop mediated isothermal amplification and PCR) 
such that ISTp failed to detect more cases of malaria 
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in pregnancy than SSTp despite more frequent testing 
[Ahmed, pers. comm.].
Pregnant women were happy to be screened for 
malaria at regular intervals even when asymptomatic. 
More importantly women perceived screening and treat-
ment as part of a “complete” ANC package and necessary 
for maintaining good health during pregnancy. Women 
frequently listed health as a primary motivating factor for 
attending ANC and accepting the services on offer, with 
some women indicating that trust in the health provider 
reassured them when offered an intervention. A similar 
study in Ghana found that women were less concerned 
by which intervention was offered, accepting both ISTp 
and IPTp, since they were part of ANC services that 
they trusted and viewed positively [16, 23]. In this study, 
acceptability towards regular screening for malaria was 
high amongst both users and providers, likely due to the 
existing culture of screening created by the current SSTp 
policy in Indonesia. In contrast, a study from Northern 
Ghana assessing acceptability to ISTp compared to cur-
rent policy of IPTp found that pregnant women disliked 
frequent blood testing. Some women reportedly asked 
for IPTp-SP to be given instead of undergoing regular 
screening [24]. However, a study in western Kenya, where 
IPTp is current policy, found that women accepted ISTp 
and understood that they would only receive anti-malari-
als if they tested positive [14]. This reflects women’s trust 
in the interventions provided at ANC and supports the 
concept that women accept what is on offer.
The unavailability of RDTs in the context of the current 
SSTp policy was undoubtedly a concern among providers 
but it also raised questions about the feasibility of imple-
menting ISTp, a strategy that requires more frequent 
testing and increased numbers of RDTs. This challenge 
affected the overall acceptability of ISTp as an alternative 
strategy. With RDTs being a core element of rolling out 
ISTp to village health posts, supply issues would need to 
be addressed for health providers to fully back a policy 
change. Furthermore, even with a regular supply chain 
the issue of RDT accuracy would still present a signifi-
cant barrier to acceptability. The effect of implementation 
issues on provider acceptability and use of new technol-
ogy has been described by a study in Uganda exploring 
provider experiences with RDTs in resource-limited set-
tings [22]. Health providers in western Kenya expressed 
reservations with regards to the reliance of the ISTp strat-
egy on RDTs, noting that they were expensive and the 
results often unreliable [14].
As frontline ANC staff providing services in the vil-
lages, midwives were more concerned with providing 
essential services that are accessible to women than the 
technical efficacy of RDTs. This was demonstrated by 
midwives’ preference for screening to be carried out at 
the rural health posts, as they were more accessible to 
pregnant women than the larger health centres. Health 
providers in general struggled with the concept of giving 
pregnant women drugs without a positive diagnostic test. 
Primarily, giving anti-malarials presumptively was against 
current national policy, but there were also concerns 
about causing potential harm to mother and baby and of 
driving drug resistance. This view is a sharp contrast to 
studies from Africa where IPTp is widely used to prevent 
malaria in pregnancy, and health provider acceptance of 
prevention over treatment is strong [13, 15]. In contrast, 
in Sumba and Mimika the concept of giving drugs before 
receiving a positive test was seen as a form of malprac-
tice with some providers emphatically stating they would 
never do such a thing. The current policy of SSTp has 
invariably fostered a culture of screening before treatment 
and as such a strategy shift from SSTp to ISTp was con-
ceptually easier to accept than a shift to IPTp. User and 
provider acceptance towards ISTp will likely be influ-
enced by whether the existing policy is based on screen-
and-treat and/or presumptive treatment; should the new 
policy require a major shift in approach, such as from 
SSTp to IPTp, there could be resistance among providers.
A key point needing further investigation is whether 
health providers perceived the use of anti-malarials for 
prevention in the same negative light that they seemed to 
view the general dispensing of medication without con-
firmation of a test result. Some insight into this question 
may be seen in health provider’s reactions to differences 
in the way the interviewer structured the question about 
IPTp. Providers were more open to the concept of IPTp if 
the interviewer described giving anti-malarials for “pre-
vention” within the context of a clinical trial instead of 
simply asking if they would ever give anti-malarial drugs 
without screening first. This could represent bias within 
the trial context, but perhaps it demonstrates that with 
the appropriate communication, training and policy 
guidelines health providers may potentially be recep-
tive to IPTp as a preventative strategy, but this would 
require careful monitoring. It further highlights the need 
to develop an effective behaviour change communica-
tion strategy to foster acceptance to IPTp among health 
providers prior to any new policy implementation. Inter-
estingly, health providers in areas with the highest preva-
lence of parasitaemia in pregnancy in Papua appeared 
more receptive to IPTp as a control strategy, perhaps 
based a on perceived greater need, an area worth further 
exploration. This perception was supported in the trial 
results, which showed that IPTp was more effective than 
SSTp in reducing the incidence of malaria during preg-
nancy and at delivery in the higher transmission sites in 
Papua [Ahmed, pers. comm.]. Crucially, for IPTp to be 
feasible midwives will need to dispense anti-malarials at 
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health posts, a concept that was acceptable to many pro-
viders, particularly in Mimika district.
Interestingly, the women in this study did not share this 
apprehension for taking anti-malarials presumptively, 
even when they experienced side effects, with many 
favouring prevention over cure. This could be due to con-
cerns about the effects of malaria in pregnancy and pre-
vious experiences of malaria infections. Health providers 
frequently reported that women would object to taking 
anti-malarials without testing positive and, while some 
women in the IPTp arm expressed hesitation over con-
cerns of side effects or harm to the baby, the vast majority 
were happy to take the preventative dose and said they 
would do so again in a future pregnancy.
Acceptance towards DP as treatment for RDT positive 
cases within the ISTp trial arm was strong among health 
providers, who felt it was well tolerated by women and 
effective in treating malaria. Pregnant women in the IPTp 
arm reported side effects including nausea, vomiting and 
dizziness but this did not seem to act as a barrier to use. 
These side effects have been reported elsewhere in Africa 
in trials of DP as an alternative drug for treatment and 
for IPTp [12, 14]. However, even mild side effects have 
contributed to the lack of effective coverage for IPTp-
SP across Africa despite decades of implementation 
with several studies reporting side effects as a barrier to 
uptake of IPTp [25, 26]. Importantly, DP was seen as an 
effective treatment and preferable due to the shorter dos-
ing regimen when compared with quinine. Regardless of 
the malaria in pregnancy strategy, supply chain issues for 
DP will need to be addressed as stock outs for first line 
treatment in the general population were widely reported 
in the national programme in Sumba.
Limitations
The opinions and experiences of health providers and 
pregnant women interviewed within the context of a 
trial cannot be generalized to non-trial settings. Social 
desirability bias may have influenced provider responses 
regarding aspects of the trial and their attitude towards 
administering anti-malarials presumptively in the IPTp 
trial arm. Similarly, there could be a bias towards report-
ing positive opinions about the interventions used in the 
trial among pregnant women. Women selected to par-
ticipate in the FGDs could differ from those who did not 
participate in a way that excludes some views from the 
data, however, the researchers agreed that saturation of 
women’s opinions was reached during the analysis of the 
FGDs. The results from this study have limited general-
izability beyond the population sampled but steps were 
taken to explore a wide variety of attitudes and opin-
ions by interviewing participants across different health 
provider cadres and pregnant women across all interven-
tion arms.
Conclusions
Acceptability of screening women at every ANC visit 
(ISTp) was high among providers and pregnant women, 
owing to an existing policy and culture of screening 
women at ANC and providing treatment based on a posi-
tive diagnosis. However, more sensitive RDTs and a reli-
able supply chain will be required to garner full approval 
among health providers. Providers were hesitant to sup-
port giving anti-malarials presumptively (IPTp) suggest-
ing a strong campaign of effective communication and 
training would be required to achieve a conceptual shift. 
Encouragingly, women were happy with any opportunity 
to prevent malaria in pregnancy and accepted IPTp as 
part of a package of valued ANC services.
In the context of this study, replacing SSTp with IPTp 
would appear to require a more challenging conceptual 
shift for providers but its superior efficacy and non-reli-
ance on RDTs means that providers may be persuaded to 
see it as a more realistic strategy in higher transmission 
settings in Indonesia.
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